Cancer play Kolltan files for IPO

Kolltan Pharmaceuticals Inc. (New Haven, Conn.) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Leerink Partners; Stifel; Guggenheim Securities; and Janney Montgomery Scott.

Kolltan's KTN3379 is in Phase I testing to treat solid tumors. Next half, Kolltan expects to announce Phase I results and start Phase II testing of the human mAb against epidermal growth factor receptor 3 ( EGFR3; HER3; ErbB3) in solid tumors. ...